PVLA
Palvella Therapeutics Inc

156
Mkt Cap
$1.12B
Volume
245,899.00
52W High
$104.91
52W Low
$11.17
PE Ratio
-7.52
PVLA Fundamentals
Price
$99.99
Prev Close
$94.87
Open
$95.23
50D MA
$73.68
Beta
0.96
Avg. Volume
176,415.39
EPS (Annual)
-$7.83
P/B
27.19
Rev/Employee
$0.00
Loading...
Loading...
News
all
press releases
Palvella Therapeutics (NASDAQ:PVLA) Reaches New 52-Week High - What's Next?
Palvella Therapeutics (NASDAQ:PVLA) Reaches New 52-Week High - Time to Buy...
MarketBeat·10h ago
News Placeholder
More News
News Placeholder
Palvella Therapeutics (NASDAQ:PVLA) Stock Price Up 7.9% - Should You Buy?
Palvella Therapeutics (NASDAQ:PVLA) Trading Up 7.9% - Time to Buy...
MarketBeat·1d ago
News Placeholder
Insider Selling: Palvella Therapeutics (NASDAQ:PVLA) COO Sells 4,302 Shares of Stock
Palvella Therapeutics, Inc. (NASDAQ:PVLA - Get Free Report) COO Kathleen Goin sold 4,302 shares of the stock in a transaction dated Wednesday, November 19th. The shares were sold at an average price...
MarketBeat·4d ago
News Placeholder
Kathleen Goin Sells 4,302 Shares of Palvella Therapeutics (NASDAQ:PVLA) Stock
Palvella Therapeutics, Inc. (NASDAQ:PVLA - Get Free Report) COO Kathleen Goin sold 4,302 shares of the business's stock in a transaction dated Wednesday, November 19th. The stock was sold at an...
MarketBeat·4d ago
News Placeholder
Palvella Therapeutics (NASDAQ:PVLA) Shares Gap Up Following Analyst Upgrade
Palvella Therapeutics (NASDAQ:PVLA) Shares Gap Up Following Analyst Upgrade...
MarketBeat·6d ago
News Placeholder
Raymond James Financial Upgrades Palvella Therapeutics (NASDAQ:PVLA) to Strong-Buy
Raymond James Financial raised Palvella Therapeutics from an "outperform" rating to a "strong-buy" rating and lifted their price target for the stock from $92.00 to $143.00 in a research report on...
MarketBeat·6d ago
News Placeholder
Cantor Fitzgerald Issues Negative Estimate for PVLA Earnings
Palvella Therapeutics, Inc. (NASDAQ:PVLA - Free Report) - Research analysts at Cantor Fitzgerald lowered their FY2025 earnings per share estimates for Palvella Therapeutics in a note issued to...
MarketBeat·10d ago
News Placeholder
FY2025 Earnings Estimate for PVLA Issued By HC Wainwright
Palvella Therapeutics, Inc. (NASDAQ:PVLA - Free Report) - HC Wainwright cut their FY2025 earnings per share (EPS) estimates for Palvella Therapeutics in a report issued on Wednesday, November 12th...
MarketBeat·11d ago
News Placeholder
What is Lifesci Capital's Forecast for PVLA FY2025 Earnings?
Palvella Therapeutics, Inc. (NASDAQ:PVLA - Free Report) - Analysts at Lifesci Capital cut their FY2025 earnings estimates for shares of Palvella Therapeutics in a research report issued on Tuesday...
MarketBeat·11d ago
News Placeholder
Canaccord Genuity Group Raises Palvella Therapeutics (NASDAQ:PVLA) Price Target to $148.00
Canaccord Genuity Group boosted their price objective on Palvella Therapeutics from $90.00 to $148.00 and gave the stock a "buy" rating in a research note on Thursday...
MarketBeat·12d ago

Latest PVLA News

View

Advertisement|Remove ads.

Advertisement|Remove ads.